Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients

• Main Authors: Rikako Ueda (Author), Naho Yamamoto (Author), Yuki Hori (Author), Kouji Yoshida (Author), Koushiro Ohtsubo (Author), Takeshi Terashima (Author), Tsutomu Shimada (Author), Yoshimichi Sai (Author)
• Format: Book
• Published: BMC, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Gemcitabine plus nab-paclitaxel (GnP) therapy is used for unresectable pancreatic ductal adenocarcinoma, but may cause interstitial lung disease (ILD) as a serious side effect. However, the risk factors for ILD in patients receiving GnP therapy are not well established. Here, we...